Immunic, INC. (IMUX) — SEC Filings

Overview

Immunic, INC. (IMUX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-8 filed on Apr 9, 2026: On April 9, 2026, IMMUNIC, INC. filed an S-8 form with the SEC, registering an unspecified number of securities to be offered under its employee benefit plans. This filing indicates the company is making shares available for its employees, likely as part of compensation or incentive programs. The fi

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 3 bullish, 3 bearish, 44 neutral. The dominant filing sentiment for Immunic, INC. is neutral.

Filing Type Overview

Immunic, INC. (IMUX) has filed 1 S-8, 26 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 8 SC 13G/A, 4 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• IMMUNIC, INC. Files S-8 for Employee Stock Plans — S-8 · Apr 9, 2026 Risk: low
  On April 9, 2026, IMMUNIC, INC. filed an S-8 form with the SEC, registering an unspecified number of securities to be offered under its employee benefit plans.
• 8-K Filing — 8-K · Apr 1, 2026
• Immunic Appoints New CMO, Dr. Feldmann — 8-K · Mar 31, 2026 Risk: medium
  On March 31, 2026, IMMUNIC, INC. filed an 8-K report detailing the departure of Dr. Andreas Marneropoulos as Chief Medical Officer, effective March 27, 2026. Th
• Immunic's Losses Widen Amidst R&D Spend, Liquidity Concerns Mount — 10-Q · Nov 13, 2025 Risk: high
  Immunic, Inc. (IMUX) reported a net loss of $25.579 million for the three months ended September 30, 2025, an increase from $24.368 million in the prior-year pe
• IMMUNIC, INC. Files 8-K on Financials — 8-K · Nov 13, 2025 Risk: low
  On November 13, 2025, IMMUNIC, INC. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as f
• IMMUNIC, INC. Files 8-K Report — 8-K · Sep 25, 2025 Risk: low
  On September 25, 2025, IMMUNIC, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific fina
• IMMUNIC's Losses Widen Amid Increased R&D Spend — 10-Q · Aug 7, 2025 Risk: high
  IMMUNIC, INC. reported a net loss of $20.9 million for the three months ended June 30, 2025, a significant increase from the $16.7 million net loss in the same
• IMMUNIC, INC. Files 8-K for Operations and Financial Condition — 8-K · Aug 7, 2025 Risk: low
  On August 7, 2025, IMMUNIC, INC. (IMUX) reported its financial results and condition. The filing does not contain specific financial figures or operational deta
• Immunic, Inc. Announces Board Changes and Compensation Updates — 8-K · Jul 11, 2025 Risk: medium
  On July 7, 2025, IMMUNIC, INC. reported a change in its board of directors, with the departure of Dr. Andreas M. Marneros and the appointment of Dr. Paul W. Smi
• IMMUNIC Faces Nasdaq Delisting Over Bid Price — 8-K · Jun 27, 2025 Risk: high
  On June 27, 2025, IMMUNIC, INC. filed an 8-K report indicating a potential delisting from the Nasdaq Capital Market. The company received a deficiency letter fr
• IMMUNIC, INC. Files 8-K: Director Changes & Officer Compensation Updates — 8-K · Jun 4, 2025 Risk: medium
  On June 4, 2025, IMMUNIC, INC. filed an 8-K report detailing several key events. The company announced the departure of a director, the election of new director
• IMMUNIC, INC. Files 8-K: Material Agreement — 8-K · May 30, 2025 Risk: medium
  On May 28, 2025, IMMUNIC, INC. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements and exh
• IMMUNIC, INC. Files 8-K Report — 8-K · May 28, 2025 Risk: low
  On May 28, 2025, IMMUNIC, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial
• IMMUNIC, INC. Files Q1 2025 10-Q Report — 10-Q · May 15, 2025 Risk: low
  IMMUNIC, INC. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as VITAL THERAPIES INC, is based in New York and oper
• 8-K Filing — 8-K · Apr 30, 2025
• Immuno, Inc. Files Definitive Proxy Statement for 2025 Annual Meeting — DEF 14A · Apr 22, 2025 Risk: low
  Immuno, Inc. filed its definitive proxy statement on April 22, 2025, for its annual meeting of stockholders scheduled for June 4, 2025. The filing outlines the
• IMMUNIC, INC. Files 8-K with Material Agreements and Equity Sales — 8-K · Apr 9, 2025 Risk: medium
  On April 9, 2025, IMMUNIC, INC. filed an 8-K report detailing several key events. The company entered into a material definitive agreement and reported unregist
• 10-K Filing — 10-K · Mar 31, 2025
• IMMUNIC, INC. Files 8-K Report — 8-K · Feb 20, 2025 Risk: low
  On February 20, 2025, IMMUNIC, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or ot
• Immunic, Inc. Files Form 8-K — 8-K · Jan 13, 2025 Risk: medium
  On January 13, 2025, Immunic, Inc. reported an event under Item 8.01 of its Form 8-K. The filing does not contain specific details about the nature of the event
• Dr. Daniel S. von Hoff Joins IMMUNIC Board — 8-K · Dec 18, 2024 Risk: low
  On December 13, 2024, IMMUNIC, INC. filed an 8-K report detailing the election of Dr. Daniel S. von Hoff as a Class II director, effective immediately. Dr. von
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 12, 2024
• IMMUNIC, INC. Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  IMMUNIC, INC. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as VITAL THERAPIES INC, is based in New York and operates in
• IMMUNIC, INC. Files 8-K: Operations, Financials, and Exhibits — 8-K · Nov 7, 2024 Risk: medium
  On November 7, 2024, IMMUNIC, INC. filed an 8-K report detailing significant corporate events. The filing includes information on the company's results of opera
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• IMMUNIC, INC. Files 8-K Report — 8-K · Oct 22, 2024 Risk: low
  On October 22, 2024, IMMUNIC, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or oth
• IMMUNIC, INC. Files 8-K Report — 8-K · Sep 10, 2024 Risk: low
  On September 10, 2024, IMMUNIC, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific fina
• IMMUNIC, INC. Files 8-K for Material Definitive Agreement — 8-K · Sep 3, 2024 Risk: medium
  On August 29, 2024, IMMUNIC, INC. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company, incorp
• IMMUNIC, INC. Files Q2 2024 10-Q Report — 10-Q · Aug 8, 2024 Risk: medium
  IMMUNIC, INC. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations. Key fi
• IMMUNIC, INC. Files 8-K: Operations & Financial Update — 8-K · Aug 8, 2024 Risk: medium
  On August 8, 2024, IMMUNIC, INC. filed an 8-K report detailing the results of operations and financial condition, along with other events and financial statemen
• IMMUNIC, INC. Files 8-K: Board Changes and Executive Compensation Updates — 8-K · Jul 24, 2024 Risk: medium
  On July 21, 2024, IMMUNIC, INC. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election of
• IMMUNIC, INC. Files 8-K: Board and Compensation Updates — 8-K · Jul 9, 2024 Risk: medium
  On July 9, 2024, IMMUNIC, INC. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing includes the
• IMMUNIC, INC. Stockholders Elect Directors, Ratify Auditors — 8-K · Jun 13, 2024 Risk: low
  On June 11, 2024, IMMUNIC, INC. filed an 8-K to report the results of its Annual Meeting of Stockholders held on June 11, 2024. The company announced that its s
• IMMUNIC, INC. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: medium
  IMMUNIC, INC. (IMUX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. IMMUNIC, INC. filed a 10-Q report for the period ending March 31, 2024. The co
• IMMUNIC, INC. Files 8-K Report — 8-K · May 8, 2024 Risk: medium
  On May 8, 2024, IMMUNIC, INC. filed an 8-K report detailing significant corporate events. The filing includes information on the company's results of operations
• Immunic, Inc. Announces Annual Stockholder Meeting on June 11, 2024 — DEF 14A · Apr 23, 2024 Risk:
  IMMUNIC, INC. (IMUX) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Immunic, Inc. will hold its annual meeting of stockholders on June 11, 20
• IMMUNIC, INC. Reports Annual Meeting Results and Corporate Changes — 8-K · Mar 8, 2024 Risk: low
  On March 4, 2024, IMMUNIC, INC. filed an 8-K report detailing several key events. The company announced the results of its annual meeting of stockholders, inclu
• IMMUNIC, INC. Files 2023 Annual Report on Form 10-K — 10-K · Feb 22, 2024 Risk: medium
  IMMUNIC, INC. (IMUX) filed a Annual Report (10-K) with the SEC on February 22, 2024. IMMUNIC, INC. filed its 2023 Form 10-K on February 22, 2024. The company's
• IMMUNIC Files 8-K on Financial Condition and Operations — 8-K · Feb 22, 2024 Risk: low
  IMMUNIC, INC. filed an 8-K on February 22, 2024, reporting on its results of operations and financial condition, as well as other events and financial statement
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Immunic, Inc. Announces Special Meeting of Stockholders on March 4, 2024 — DEF 14A · Feb 5, 2024 Risk: low
  IMMUNIC, INC. (IMUX) filed a Proxy Statement (DEF 14A) with the SEC on February 5, 2024. Immunic, Inc. is holding a special meeting of stockholders on March 4,
• Janus Henderson Group Takes 7.4% Stake in Immunic, Inc. — SC 13G · Jan 18, 2024
  Janus Henderson Group plc, a major investment firm, reported on January 18, 2024, that it now beneficially owns 7.4% of Immunic, Inc.'s Common Stock. This signi
• Biotechnology Value Fund L.P. Takes New Passive Stake in Immunic, Inc. — SC 13G · Jan 18, 2024
  Biotechnology Value Fund L.P. has reported a new passive stake in Immunic, Inc. (IMUX) as of January 8, 2024. This filing, an SC 13G, indicates that Biotechnolo
• Avidity Partners Discloses 9.9% Stake in Immunic (IMUX) — SC 13G · Jan 16, 2024
  Avidity Partners Management LP, an investment firm based in Dallas, TX, has disclosed a significant stake in Immunic, Inc. (IMUX), a pharmaceutical company. As

Risk Profile

Risk Assessment: Of IMUX's 34 recent filings, 3 were flagged as high-risk, 16 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Immunic, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: N/A
• Net Income: -$77.872M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $35.132M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Dr. Andreas Marneropoulos
• Dr. Holger J. Feldmann
• Dr. Andreas M. Marneros
• Dr. Paul W. Smith
• Dr. Daniel S. von Hoff
• Dr. Daniel G. Welch
• Mr. David M. E. Smith

Industry Context

The biotechnology sector, particularly companies focused on novel therapeutics for neurological disorders like multiple sclerosis, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Immunic operates in a competitive landscape with established players and emerging biotechs, where clinical trial success and regulatory approval are paramount for market entry and commercial viability.

Top Tags

sec-filing (6) · 8-k (6) · financials (5) · financial-condition (4) · operations (4) · board-changes (4) · 10-Q (4) · 8-K (4) · executive-compensation (3) · corporate-governance (3)

Key Numbers

• Annual Base Salary: $400,000 — For the new Chief Medical Officer, Dr. Holger J. Feldmann.
• Net Loss (9 months): $77.872M — Increased from $75.332M in 2024, indicating widening losses.
• R&D Expenses (9 months): $62.914M — Increased from $58.429M in 2024, showing continued investment in pipeline.
• Cash & Cash Equivalents: $35.132M — As of Sept 30, 2025, insufficient for 12 months of operations.
• Accumulated Deficit: $589.3M — As of Sept 30, 2025, highlighting historical unprofitability.
• May 2025 Offering Proceeds: $60.661M — Key financing obtained, but still insufficient for long-term liquidity.
• Net Cash Used in Operating Activities (9 months): $66.525M — Increased from $61.803M in 2024, indicating accelerating cash burn.
• Weighted-Average Common Shares Outstanding (Q3): 193,897,764 — Significantly increased from 101,272,580 in Q3 2024, indicating substantial dilution.
• Net Loss (Q2 2025): $20.9M — Increased from $16.7M in Q2 2024, indicating widening losses.
• Net Loss (YTD June 2025): $40.8M — Increased from $33.0M in YTD June 2024, reflecting higher operational costs.
• R&D Expenses (Q2 2025): $17.5M — Up from $14.2M in Q2 2024, driven by increased clinical trial activity.
• April 2025 PIPE Proceeds: $10.0M — Capital raised to fund operations, indicating reliance on external financing.
• May 2025 PIPE Proceeds: $15.0M — Additional capital raised, contributing to potential shareholder dilution.
• Minimum Bid Price: $1.00 — The minimum price per share required by Nasdaq to remain listed.
• Compliance Period: 180 days — The timeframe IMMUNIC has to meet the minimum bid price requirement.

Related Companies

NDAQ

Frequently Asked Questions